In honor of the holiday weekend, the Gumshoe is essentially taking a holiday, too. I hope the Americans among you have a great break, if you get one, and that you have a chance to honor the service and memory of so many who have served our country.
But in case you’re looking for some teaser stock action to research, I thought I’d share one with you that has just recently returned to heavy rotation — it’s coming in from several different mailing lists, and many of you have forwarded it to me in the past week.
The ad is still for the Access Group from Marc Lichtenfeld … and it’s still teasing us about the same skin cancer detection stock that it was a few months ago when we first saw it.
The short answer is that the stock is Electro-Optical Sciences (MELA) … and it has done very well in the couple months since we first saw it teased in newsletter ads. At that time it was bouncing around in the $4.5-$5 range, and it’s now close to $8. Certainly one of the stronger performers during that time.
To be fair, it’s still a bit short of the $196 they had as a pie-in-the-sky target, but certainly a nice couple months.
If you’d like to read what I thought about it at the time, and see what your fellow readers commented, you can review that original article here. I still find it hard to get excited about this stock, but I could easily be wrong … and so far, I have been.
Happy reading, and have a great weekend. I’m sure I’ll have some more interesting stocks to write to you about next week.
I've used MarketClub in the past when thinking about timing entry and exit points, and it's worth trying it to see if it works for you.
They have a free trial right now (they don't even ask for a credit card, this is ACTUALLY free), so now's the time to give it a try.
Claim your free 2-week trial to MarketClub – No credit card required! But hurry, this offer ends Friday, July 13.
Just request access and they’ll send you a username and password right away.
In just a few moments from now, you’ll have access to MarketClub’s powerful scans, signals, charts, alerts, and more.
You’ll need to accept this free trial before this offer expires on Friday.